Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA
Sun Pharmaceutical Industries — Ranbaxy Laboratories — Q2 FY15 Earnings Presentation
16 slides from Sun Pharmaceutical Industries's earnings presentation, Oct 28, 2014
Slide 1: Financial Results: July – September 2014 (Q2 FY15)
Ranbaxy Laboratories Limited FINANCIAL RESULTS: July – September 2014 (Q2 FY15) YTD September 2014 (H1 FY15) ARUN SAWHNEY CEO & MD Q2 FY14 : Jul’13 to Sep’13 H1 FY14 : Apr’13 to Sep’13 Q2 FY15 : Jul’14 to Sep’14 H1 FY15 : Apr’14 to Sep’14 Dept. Name 28 October 2014 Post Results Conference Call Privi
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p
Slide 3: Ranbaxy and Sun Pharma Merger Update
Ranbaxy and Sun Pharma Merger Update High Court of Punjab and Haryana convened a meeting of equity shareholders Shareholders approved the scheme of arrangement of merger with overwhelming majority Privileged and Confidential 3
Slide 4: Key Achievements for Quarter 2, FY15
Key Achievements for Quarter 2, FY15 Financial Total Sales continued to grow over the corresponding quarter aided by sale of Valsartan in the US Ranbaxy continues to focus on creating brands and differentiated products 32,180 25% 27,502 Percent Rs. Mn 7% Q2 FY14 Q2 FY15 Q2 FY14 Q2 FY15 Sales EBI
Slide 5: Other Areas: R&D, Derivatives Position, Debt
Other Areas Research & Development and Regulatory DF filings: 68; DF approvals:38 Derivatives Position Exposure down to ~$373 Mn as on 30 Sep 2014 from ~$470 Mn on 30st Jun 2014. Maturity: ~$32 Mn/month Debt Debt $1,078 Mn; Cash & Bank $339 Mn Net Debt $739 Mn Privileged and Confidential 5
Slide 6: Financial Performance
Ranbaxy Laboratories Limited Financial Performance FINANCIAL RESULTS: July – September 2014 (Q2 FY15) YTD September 2014 (H1 FY15) Dept. Name Privileged and Confidential
Slide 7: Consolidated Sales Performance
Consolidated Sales Performance Rs. Mn 55,902 53,341 32,180 27,502 21% 5% Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Total sales grew by 21% aided by sales of Valsartan in US, Sales in Western Europe and India Growth calculated on Constant Forex Privileged and Confidential 7
Slide 8: North America
North America Rs. Mn Major markets -USA 21,770 -Canada 16,777 14,153 8,754 66% 29% Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Successfully monetized our FTF exclusivity of Valsartan Strong sales growth in Absorica™ continued Growth calculated on Constant Forex Privileged and Confidential 8
Slide 9: India
India Rs. Mn 12,512 11,173 6,438 5,748 12% 12% Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Primary sales grew over the corresponding quarter India region witnessed resurgence in its prime segments within the branded business Growth calculated on Constant Forex Privileged and Confidential 9
Slide 10: East Europe & CIS
East Europe & CIS Rs. Mn Major markets 8,032 -Romania 7,434 -Russia -Ukraine 4,771 4,045 (7%) (4%) Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Sales were mainly impacted by weak ARV sales in Russia Growth calculated on Constant Forex Privileged and Confidential 10
Slide 11: West Europe
West Europe Rs. Mn Major markets -France 4,764 -Germany 3,980 -UK 2,330 2,023 17% 13% Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Regional focus on profitability continued Growth was driven by strong performance in UK, Germany, Spain and NEA regions Growth calculated on Constant Forex Privileged and Confide
Slide 12: Asia Pacific & Latin America
Asia Pacific & Latin America Rs. Mn Major markets -ANZ -Malaysia 4,273 -Brazil 3,425 2,232 1,870 (15%) (20%) Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Negatively impacted by change in business model in Thailand and sales return in Malyasia Sales grew in Australia, the largest market in the APAC region (ex
Slide 13: Africa & Middle East
Africa & Middle East Rs. Mn 5,286 Major markets 4,514 -South Africa -Nigeria 2,458 2,365 (13%) 1% Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Witnesses strong growth in our Core business Growth was muted due to lower ARV business over the corresponding quarter Growth calculated on Constant Forex Privileged
Slide 14: API & Others
API & Others Rs. Mn 3,737 1,474 1,389 935 (35%) (63%) Q2 FY14 Q2 FY15 H1 FY14 H1 FY15 Sales impacted by supply issues Growth calculated on Constant Forex Privileged and Confidential 14
Slide 15: Financials Q2 FY15: INR
Financials Q2 FY15: INR Q2 FY14 YTD Sep FY14 Particulars Q2 FY15 YTD Sep FY15 5,911 11,472 -Within India 6,813 13,029 21,591 41,869 -Outside India 25,367 42,874 27,502 53,341 Sales 32,180 55,902 515 1,017 Other operating income 425 863 28,016 54,358 Total Operating Income 32,605 56,765 5,921 11,559
Slide 16: Questions & Answers
Questions & Answers Dept. Name Privileged and Confidential